Harvard Apparatus Regenerative Technology, Inc.

HRGN

CIK 0001563665 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$219K
↓-15.1% -$39Kvs FY2024 (Q4)
Gross Profit
$20K
↓-75.9% -$63Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
23/100
  • Profitability
    0ROIC -255.3% (10% = solid, 20%+ = moat)
  • Liquidity
    35Current Ratio 1.19 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover 0.20x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -15.1% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -1393.5% · trend +1814.7pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
investment in PP&E
Stock buybacks (TTM)
share count reduction
Stock-based comp (TTM)
$2M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$3M
everything owned
Total liabilities
$2M
everything owed
Stockholders' equity
$1M
shareholder claim

Recent performance · 56 quarters

Revenue↓-15.1% -$39K
$219K
Net Income↑+8.6% +$160K
$-2M
Free Cash Flow↑+21.0% +$202K
$-758K
Operating Margin↑+1757.4pts
-1393.5%

Drill down